The following represents disclosure information provided by authors of this abstract. The ASCO Scientific Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
Dual antiangiogenic therapy using lenalidomide and bevacizumab with docetaxel and prednisone in patients with metastatic castration-resistant prostate cancer (mCRPC).
Bamidele Adesunloye
No relevant relationships to disclose
Xuan Huang
No relevant relationships to disclose
Yangmin M. Ning
No relevant relationships to disclose
Ravi A. Madan
No relevant relationships to disclose
James L. Gulley
No relevant relationships to disclose
Melony Beatson
No relevant relationships to disclose
Paul Gustav Kluetz
No relevant relationships to disclose
David E. Adelberg
No relevant relationships to disclose
Philip M. Arlen
No relevant relationships to disclose
Howard L. Parnes
No relevant relationships to disclose
Marcia Mulquin
No relevant relationships to disclose
Seth M. Steinberg
No relevant relationships to disclose
John Joseph Wright
No relevant relationships to disclose
Jane B. Trepel
No relevant relationships to disclose
Nancy Ann Dawson
No relevant relationships to disclose
Clara Chen
No relevant relationships to disclose
Carol Bassim
No relevant relationships to disclose
Andrea Borghese Apolo
No relevant relationships to disclose
William Douglas Figg
No relevant relationships to disclose
William L. Dahut
No relevant relationships to disclose